Christopherj Senner News Today

William Blair restated their outperform rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research report report published on Monday morning, RTT News reports. William Blair also issued estimates for Exelixis’ Q3 2023 earnings at ($0.05) EPS and FY2023 earnings at $0.45 EPS. EXEL has been the topic of several other research reports. […]

Creative Planning decreased its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 10.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 86,312 shares of the biotechnology company’s stock after selling 10,419 shares during the period. Creative Planning’s holdings in Exelixis were worth […]

Capital Management Corp VA boosted its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 2.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 363,354 shares of the biotechnology company’s stock after purchasing an additional 9,539 shares during the quarter. Capital Management Corp VA’s […]

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 8,400,000 shares, a growth of 6.6% from the August 31st total of 7,880,000 shares. Based on an average daily trading volume, of 2,230,000 shares, […]

HC Wainwright began coverage on shares of Exelixis (NASDAQ:EXEL – Free Report) in a report issued on Tuesday morning, MarketBeat reports. The brokerage issued a buy rating and a $28.00 target price on the biotechnology company’s stock. A number of other equities analysts have also commented on the stock. Barclays cut their price objective on […]

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the fourteen analysts that are currently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective […]

Candriam S.C.A. lessened its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 31.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,536,921 shares of the biotechnology company’s stock after selling 706,117 shares during the quarter. Candriam […]

Exelixis (NASDAQ:EXEL – Free Report) had its price target raised by JMP Securities from $24.00 to $27.00 in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. EXEL has been the subject of a number of other research reports. StockNews.com initiated […]

South Dakota Investment Council grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 19.3% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 185,162 shares of the biotechnology company’s stock after purchasing an additional 30,000 shares during the period. South Dakota […]

South Dakota Investment Council boosted its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 19.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 185,162 shares of the biotechnology company’s stock after purchasing an additional 30,000 shares during the period. […]